P3 Health Partners Inc. Annual report pursuant to Section 13 and 15(d)

Schedule of weighted average assumptions used in estimating the grant date fair value of stock options


	Year Ended
	December 31,
	2022
Expected volatility	51	%
Risk-free interest rate	3.2	%
Expected term (in years)	7.28
Dividend rate	0.0	%

Time-based stock options

Schedule of stock option activity


				Weighted
				Average
		Weighted		Remaining	Aggregate
	Number of	Average		Contractual	Intrinsic
	Stock Options	Exercise		Life	Value
	(in thousands)	Price		(in years)	(in thousands)
Outstanding at December 31, 2021	—	$	—
Granted	3,589		5.57
Forfeited	(187)		5.02
Outstanding at December 31, 2022	3,402	$	5.60	9.62	$	—
Fully vested and expected to vest at December 31, 2022	3,402	$	5.60	9.62	$	—
Exercisable at December 31, 2022	117	$	5.02	9.22	$	—

Performance-based stock options

Schedule of stock option activity


				Weighted
				Average
		Weighted		Remaining	Aggregate
	Number of	Average		Contractual	Intrinsic
	Stock Options	Exercise		Life	Value
	(in thousands)	Price		(in years)	(in thousands)
Outstanding at December 31, 2021	—	$	—
Granted	1,500		4.95
Outstanding at December 31, 2022	1,500	$	4.95	9.83	$	—
Fully vested and expected to vest at December 31, 2022	1,500	$	4.95	9.83	$	—
Exercisable at December 31, 2022	—	$	—	—	$	—

Common Unit award

Schedule of common unit award activity


	Weighted
	Average		Number of
	Grant-Date		Units
	Fair Value		(in thousands)
Non-vested at December 31, 2021	$	9.20	5,471
Granted		—	—
Vested		9.20	(5,038)
Forfeited		9.20	(53)
Non-vested at December 31, 2022	$	9.20	380

Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.

Name:	us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.